Project Grant R01CA309823
Award Date 3/18/26
Completion Date 2/28/31
Dollars Obligated $658K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15222, USA
Similar Awards
- Federal Grant Award Summary The University of Pittsburgh received a $408,829 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2025, through May 31, 2027. This award supports the development of positive allosteric modulators (PAMs) targeting XCR1, a chemokine receptor expressed on conventional dendritic cells subtype 1 (CDC1s). The research will utilize DNA-encoded library (DEL) technology and cryo-electron...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $156,426 to the University of Pittsburgh under the Cancer Research Manpower program (CFDA 93.398) to support an integrated in silico and in vivo genetic screening research project. The award, initiated December 1, 2025, with completion targeted for April 16, 2029, funds the development of subtype-specific precision therapeutic approaches for hepatocellular carcinoma (HCC). The research employs a hybrid methodology...
- Federal Grant Award Summary The University of Pittsburgh received a $109,076 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded January 21, 2026, with completion targeted for July 31, 2029. This grant funds research on "Metastatic Tracking of Cancer Subclones for Collateral Lethality Prediction," which aims to advance understanding of genomic evolution in late-stage metastatic breast cancer through computational...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Project Grant Award Summary The University of Pittsburgh received a $169,982 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded August 8, 2025, with a completion date of July 31, 2030. The Program in Cancer Training and Education (PICTE) will deliver an intensive, multi-phase research and professional development initiative for ten rising sophomore and junior undergraduates selected from the university's student...
- Federal Project Grant Award Summary The University of Pittsburgh has been awarded $151,920 under the Cancer Biology Research program (CFDA 93.396) by the National Cancer Institute for a two-year project (September 1, 2025 – August 31, 2027). This project grant supports fundamental research focused on developing nuclear magnetic resonance (NMR) strategies to investigate allosteric inhibitor binding effects on Src-family kinases implicated in acute myeloid leukemia (AML). The research addresses...
- Federal Grant Award Summary The University of Pittsburgh received a $151,040 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 12, 2025, with completion targeted for November 30, 2027. The award supports research investigating the relative and synergistic contributions of Programmed Cell-Death-1 (PD1) and Lymphocyte Activation Gene 3 (LAG3) inhibitory receptors on CD4+ T conventional cells in cancer. The research...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760.00 to The Regents of the University of California, San Francisco under the Cancer Research Manpower program (CFDA 93.398) on July 7, 2025. This Project Grant funds research aimed at enhancing treatment outcomes for metastatic castration-resistant prostate cancer (MCRPC) through the development of novel tumor-targeted combination therapy. The primary research deliverable involves creating a single...
- Federal Grant Award Summary The National Cancer Institute awarded a $410,933 Project Grant (Cancer Treatment Research, CFDA 93.395) to the University of California, San Diego, effective March 18, 2026, through February 29, 2028. This exploratory research initiative (R21 mechanism) aims to develop next-generation small interfering RNA (siRNA) therapeutics to treat metastatic castration-resistant prostate cancer (mCRPC). The project focuses on enhancing siRNA delivery into mCRPC tumor cells by...
- Federal Project Grant Award Summary The University of Pittsburgh received a $1,008,763 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award supports research investigating profilin-1's role in chromophobe renal cell carcinoma (RCC) mitochondria and tumorigenesis. This four-year project conducts hypothesis-driven biomedical research aimed at advancing understanding...